{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-23-000024","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.586191+00:00","generated_at":"2026-06-12T07:27:51.634400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xencor Q2 2023 revenue $45.5M up 51% YoY; net loss narrows to $22M; pipeline advances","bullets":["Revenue $45.5M (vs $30.2M Q2 2022), net loss $22.0M ($0.37/diluted) vs $34.0M loss ($0.57) prior.","Cash, equivalents and marketable securities $531.4M at June 30, 2023, down from $613.5M at Dec 31, 2022.","Royalty revenue from Alexion's Ultomiris $11.2M; $10M milestone from Zenas for obexelimab Phase 3 start.","R&D expenses $60.1M, up 28% YoY; guidance projects year-end cash $425-475M, funding through 2025.","Vudalimab Phase 2 front-line NSCLC expected by year-end; XmAb662 Phase 1 started; XmAb541 IND planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-23-000024","json":"https://secwatch.observer/filing/0001326732-23-000024.json","markdown":"https://secwatch.observer/filing/0001326732-23-000024.md","text":"https://secwatch.observer/filing/0001326732-23-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/0001326732-23-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/xncr-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:27:51.634400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6061443915cf3cdb2cddf4e06bf6ffed9f000963","claim":"Xencor Inc reported second quarter ended June 30, 2023 results: revenue $45.5 million.","evidence_excerpt":"Total revenue for the second quarter ended June 30, 2023 was $45.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000024/0001326732-23-000024-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$45.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}